CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Nov. 30, 2022	Nov. 30, 2021
Cash flows from operating activities
Net loss	$ (180,360)	$ (117,194)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	5,349	2,790
Stock-based compensation	28,131	15,800
Net amortization of premium on marketable securities	426	1,706
Loss on disposal of property and equipment	9	128
Amortization of operating lease right-of-use assets	5,459	3,292
Other	201	0
Changes in operating assets and liabilities:
Accounts receivable	6,000	(6,000)
Income tax receivable	0	3,642
Prepaid expenses and other assets	(1,094)	(5,442)
Accounts payable	85	1,589
Deferred revenue	(26,627)	14,250
Operating lease liabilities	(4,871)	(5,144)
Accrued expenses and other liabilities	7,485	6,218
Net cash used in operating activities	(159,807)	(84,365)
Cash flows from investing activities
Purchases of marketable securities	(239,366)	(348,497)
Sales of marketable securities	0	6,994
Maturities of marketable securities	278,808	238,913
Purchases of property and equipment	(12,244)	(5,661)
Net cash provided by (used in) investing activities	27,198	(108,251)
Cash flows from financing activities
Proceeds from issuances of pre-funded warrants, net of issuance costs	94,759	0
Proceeds from issuance of common stock	19,400	150,157
Proceeds from exercise of stock options	1,078	1,666
Proceeds from issuance under employee stock purchase plan	1,955	2,060
Repurchase of unvested early exercised stock options	0	(1)
Net cash provided by financing activities	117,192	153,882
Net decrease in cash, cash equivalents and restricted cash	(15,417)	(38,734)
Cash, cash equivalents and restricted cash at beginning of period	80,792	119,526
Cash, cash equivalents and restricted cash at end of period	65,375	80,792
Supplementary disclosures of cash flow information:
Cash paid for income taxes	0	481
Supplemental disclosures of non-cash investing and financing activities:
Additions to property and equipment included in accounts payable and accrued expenses and other liabilities	1,373	2,505
Capitalized stock-based compensation related to internal-use software development	69	0
Vesting of early exercised stock options	145	239
Deferred issuance costs recognized related to equity financing	72	0
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents	64,474	80,506
Restricted cash	901	286
Cash, cash equivalents and restricted cash	$ 65,375	$ 80,792